loading...| Preferred Name |
ertapenem sodium |
|
| Synonyms |
Invanz |
|
| Definitions |
The sodium salt of ertapenem, a 1-beta-methyl carbapenem and a broad-spectrum beta-lactam antibiotic with bactericidal activity. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition of peptidoglycan synthesis results in weakening and lysis of the cell wall and cell death. In vitro, this agent has shown activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. Erapenem is resistant to hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C61753" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61753" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000573502 |
|
| altLabel |
Invanz |
|
| CAS Registry |
153832-38-3 |
|
| cui |
C1170745 C1170351 |
|
| DATE FIRST PUBLISHED |
2007-10-12 |
|
| Date last modified |
2007-10-12 |
|
| definition |
The sodium salt of ertapenem, a 1-beta-methyl carbapenem and a broad-spectrum beta-lactam antibiotic with bactericidal activity. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition of peptidoglycan synthesis results in weakening and lysis of the cell wall and cell death. In vitro, this agent has shown activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. Erapenem is resistant to hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C61753" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61753" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C61753 |
|
| notation |
CDR0000573502 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
ertapenem sodium |
|
| tui |
T109 T121 |